Skip to content

US government will not override Abbott's ritonavir patent

US approval for once daily abacavir/3TC and tenofovir/FTC pills

Atazanavir: final phase III results published

Two-year data continue to show promise for T-20

Once daily Reverset safe and effective over ten days in treatment-naïve and –experienced patients

Intergrase inhibitor trial results have potential implications for treatment strategies

HIV Drug Resistance Workshop: entry and attachment inhibitors

Harmless virus slows HIV progression by stimulating chemokine release

Dietary supplements can improve diarrhoea and increase antiretroviral drug levels in AIDS patients